4.6 Article

Multi-predictor modeling for predicting early Parkinson's disease and non-motor symptoms progression

期刊

FRONTIERS IN AGING NEUROSCIENCE
卷 14, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fnagi.2022.977985

关键词

Parkinson's disease; predictive model; diagnosis; non-motor symptoms; progression

资金

  1. National Natural Science Foundation of China [81971192]
  2. Parkinson's Progression Markers Initiative (PPMI) - Michael J. Fox Foundation for Parkinson's Research
  3. Abbvie
  4. Avid
  5. Bristol-Myers Squibb
  6. GE Healthcare
  7. GlaxoSmithKline
  8. Lundbeck
  9. Meso Scale Discovery
  10. Pfizer
  11. Biogen
  12. Piramal
  13. BioLegend
  14. Roche
  15. Genentech
  16. Servier
  17. Lilly
  18. Takeda
  19. Merck
  20. Teva
  21. Sanofi
  22. Golub Capital
  23. UCB

向作者/读者索取更多资源

This study aimed to develop clinical risk models using non-motor predictors to distinguish between early Parkinson's disease (PD) and healthy individuals. In addition, prognostic models were constructed to predict the progression of non-motor symptoms in de novo PD patients at a 5-year follow-up.
BackgroundIdentifying individuals with high-risk Parkinson's disease (PD) at earlier stages is an urgent priority to delay disease onset and progression. In the present study, we aimed to develop and validate clinical risk models using non-motor predictors to distinguish between early PD and healthy individuals. In addition, we constructed prognostic models for predicting the progression of non-motor symptoms [cognitive impairment, Rapid-eye-movement sleep Behavior Disorder (RBD), and depression] in de novo PD patients at 5 years of follow-up. MethodsWe retrieved the data from the Parkinson's Progression Markers Initiative (PPMI) database. After a backward variable selection approach to identify predictors, logistic regression analyses were applied for diagnosis model construction, and cox proportional-hazards models were used to predict non-motor symptom progression. The predictive models were internally validated by correcting measures of predictive performance for optimism or overfitting with the bootstrap resampling approach. ResultsFor constructing diagnostic models, the final model reached a high accuracy with an area under the curve (AUC) of 0.93 (95% CI: 0.91-0.96), which included eight variables (age, gender, family history, University of Pennsylvania Smell Inventory Test score, Montreal Cognitive Assessment score, RBD Screening Questionnaire score, levels of cerebrospinal fluid alpha-synuclein, and SNCA rs356181 polymorphism). For the construction of prognostic models, our results showed that the AUC of the three prognostic models improved slightly with increasing follow-up time. The overall AUCs fluctuated around 0.70. The model validation established good discrimination and calibration for predicting PD onset and progression of non-motor symptoms. ConclusionThe findings of our study facilitate predicting the individual risk at an early stage based on the predictors derived from these models. These predictive models provide relatively reliable information to prevent PD onset and progression. However, future validation analysis is still needed to clarify these findings and provide more insight into the predictive models over more extended periods of disease progression in more diverse samples.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据